1
|
Letchumanan G, Abdullah N, Marlini M, Baharom N, Lawley B, Omar MR, Mohideen FBS, Addnan FH, Nur Fariha MM, Ismail Z, Pathmanathan SG. Gut Microbiota Composition in Prediabetes and Newly Diagnosed Type 2 Diabetes: A Systematic Review of Observational Studies. Front Cell Infect Microbiol 2022; 12:943427. [PMID: 36046745 PMCID: PMC9422273 DOI: 10.3389/fcimb.2022.943427] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Accepted: 06/20/2022] [Indexed: 11/13/2022] Open
Abstract
Evidence of gut microbiota involvement in regulating glucose metabolism and type 2 diabetes mellitus (T2DM) progression is accumulating. The understanding of microbial dysbiosis and specific alterations of gut microbiota composition that occur during the early stages of glucose intolerance, unperturbed by anti-diabetic medications, is especially essential. Hence, this systematic review was conducted to summarise the existing evidence related to microbiota composition and diversity in individuals with prediabetes (preDM) and individuals newly diagnosed with T2DM (newDM) in comparison to individuals with normal glucose tolerance (nonDM). A systematic search of the PubMed, MEDLINE and CINAHL databases were conducted from inception to February 2021 supplemented with manual searches of the list of references. The primary keywords of “type 2 diabetes”, “prediabetes”, “newly-diagnosed” and “gut microbiota” were used. Observational studies that conducted analysis of the gut microbiota of respondents with preDM and newDM were included. The quality of the studies was assessed using the modified Newcastle-Ottawa scale by independent reviewers. A total of 18 studies (5,489 participants) were included. Low gut microbial diversity was generally observed in preDM and newDM when compared to nonDM. Differences in gut microbiota composition between the disease groups and nonDM were inconsistent across the included studies. Four out of the 18 studies found increased abundance of phylum Firmicutes along with decreased abundance of Bacteroidetes in newDM. At the genus/species levels, decreased abundance of Faecalibacterium prausnitzii, Roseburia, Dialister, Flavonifractor, Alistipes, Haemophilus and Akkermansia muciniphila and increased abundance of Lactobacillus, Streptococcus, Escherichia, Veillonella and Collinsella were observed in the disease groups in at least two studies. Lactobacillus was also found to positively correlate with fasting plasma glucose (FPG), HbA1c and/or homeostatic assessment of insulin resistance (HOMA-IR) in four studies. This renders a need for further investigations on the species/strain-specific role of endogenously present Lactobacillus in glucose regulation mechanism and T2DM disease progression. Differences in dietary intake caused significant variation in specific bacterial abundances. More studies are needed to establish more consistent associations, between clinical biomarkers or dietary intake and specific gut bacterial composition in prediabetes and early T2DM.
Collapse
Affiliation(s)
- Geetha Letchumanan
- Department of Medical Sciences, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
| | - Natasya Abdullah
- Department of Medical Sciences, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
| | - Muhamad Marlini
- Department of Medical Sciences, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
| | - Nizam Baharom
- Public Health Unit, Department of Primary Health Care, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
| | - Blair Lawley
- Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand
| | - Mohd Rahman Omar
- Medical-based Department, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
| | - Fathima Begum Syed Mohideen
- Family Medicine Unit, Department of Primary Health Care, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
| | - Faizul Helmi Addnan
- Department of Medical Sciences, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
| | - Mohd Manzor Nur Fariha
- Department of Medical Sciences, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
| | - Zarini Ismail
- Department of Medical Sciences, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
| | - Siva Gowri Pathmanathan
- Department of Medical Sciences, Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia (USIM), Negeri Sembilan, Malaysia
- *Correspondence: Siva Gowri Pathmanathan,
| |
Collapse
|
2
|
Toejing P, Khat-Udomkiri N, Intakhad J, Sirilun S, Chaiyasut C, Lailerd N. Putative Mechanisms Responsible for the Antihyperglycemic Action of Lactobacillus paracasei HII01 in Experimental Type 2 Diabetic Rats. Nutrients 2020; 12:nu12103015. [PMID: 33019697 PMCID: PMC7601916 DOI: 10.3390/nu12103015] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 09/28/2020] [Accepted: 09/30/2020] [Indexed: 01/09/2023] Open
Abstract
Despite the updated knowledge of the impact of gut dysbiosis on diabetes, investigations into the beneficial effects of individual bacteria are still required. This study evaluates the antihyperglycemic efficacy of Lactobacillus paracasei HII01 and its possible mechanisms in diabetic rats. Diabetic rats were assigned to receive vehicle, L. paracasei HII01 (108 CFU/day), metformin 30 (mg/kg) or a combination of L. paracasei HII01 and metformin. Normal rats given vehicle and L. paracasei HII01 were included. Metabolic parameters, including in vitro hemi-diaphragm glucose uptake, skeletal insulin-signaling proteins, plasma lipopolysaccharide (LPS), gut permeability, composition of gut microbiota and its metabolites, as well as short-chain fatty acids (SCFAs), were assessed after 12 weeks of experiment. The results clearly demonstrated that L. paracasei HII01 improved glycemic parameters, glucose uptake, insulin-signaling proteins including pAktSer473, glucose transporter 4 (GLUT4) and phosphorylation of AMP-activated protein kinase (pAMPKThr172), tumor necrosis factor (TNF-α) and nuclear factor-κB (NF-kB) in diabetic rats. Modulation of gut microbiota was found together with improvement in leaky gut, endotoxemia and SCFAs in diabetic rats administered L. paracasei HII01. In conclusion, L. paracasei HII01 alleviated hyperglycemia in diabetic rats primarily by modulating gut microbiota along with lessening leaky gut, leading to improvement in endotoxemia and inflammation-disturbed insulin signaling, which was mediated partly by PI3K/Akt signaling and AMPK activation.
Collapse
Affiliation(s)
- Parichart Toejing
- Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; (P.T.); (J.I.)
| | - Nuntawat Khat-Udomkiri
- Innovation Center for Holistic Health, Nutraceuticals and Cosmeceuticals, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand; (N.K.-U.); (S.S.); (C.C.)
| | - Jannarong Intakhad
- Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; (P.T.); (J.I.)
| | - Sasithorn Sirilun
- Innovation Center for Holistic Health, Nutraceuticals and Cosmeceuticals, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand; (N.K.-U.); (S.S.); (C.C.)
| | - Chaiyavat Chaiyasut
- Innovation Center for Holistic Health, Nutraceuticals and Cosmeceuticals, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand; (N.K.-U.); (S.S.); (C.C.)
| | - Narissara Lailerd
- Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; (P.T.); (J.I.)
- Innovation Center for Holistic Health, Nutraceuticals and Cosmeceuticals, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand; (N.K.-U.); (S.S.); (C.C.)
- Correspondence: ; Tel.: +66-5393-5362-4
| |
Collapse
|